- Home
- NRIX vs LILAK Comparison
NRIX vs LILAK Comparison
Compare NRIX & LILAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NRIX | LILAK |
|---|---|---|
| Founded | 2009 | 2017 |
| Country | United States | Bermuda |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Cable & Other Pay Television Services |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | NRIX | LILAK |
|---|---|---|
| Price | $14.80 | $8.42 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 12 | 1 |
| Target Price | ★ $30.58 | $8.20 |
| AVG Volume (30 Days) | ★ 891.7K | 833.2K |
| Earning Date | 04-10-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $76,987,000.00 | N/A |
| Revenue This Year | N/A | $1.37 |
| Revenue Next Year | $26.32 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 99.31 | N/A |
| 52 Week Low | $8.18 | $4.23 |
| 52 Week High | $22.50 | $9.13 |
Technical Indicators
Market Signals| Indicator | NRIX | LILAK |
|---|---|---|
| Relative Strength Index (RSI) | 42.98 | 58.67 |
| Support Level | $11.34 | $7.57 |
| Resistance Level | $16.47 | $8.53 |
| Average True Range (ATR) | 0.85 | 0.36 |
| MACD | 0.05 | 0.06 |
| Stochastic Oscillator | 36.53 | 87.60 |
Price Performance
Historical ComparisonAbout NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
About LILAK Liberty Latin America Ltd. Class C
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.